Company intelligence / Profile preview

Shanghai Dongbao Biological Pharmaceutical

Jilin, China

Ownership: Private
Development stage: Other

Overview

Tonghua Dongbao Pharmaceutical is a pioneer in recombinant insulin industrialization in China, developing China's first recombinant human insulin (Gansulin) in 1998. The company has achieved significant market penetration with its insulin glargine and aspart insulin products, and recently passed EU GMP certification for human insulin drug substance production in July 2024. Its pipeline includes multiple programs across various stages, focusing on metabolic diseases.

Therapeutic areas: EndocrinologyNeurologyRheumatologyGastroenterologyMetabolic Disorders
Modalities: Recombinant proteinHormonePeptidesSmall molecule
Industry: Biotech

Partnerships

Sinopharm GroupBeijing Quality Peptide BiopharmaceuticalWuXi AppTecAdociaNanjing Kingfriend Biochemical Pharmaceutical

Beyond the preview

Go deeper on Shanghai Dongbao Biological Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Dongbao Biological Pharmaceutical.

Explore the full profile